InVivo Therapeutics Announces New Site for INSPIRE Study
April 10 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that the Brigham and Women’s Hospital (BWH) in Boston, MA
has been added as a clinical site for The INSPIRE Study:
InVivo Study of Probable Benefit of the Neuro-Spinal
Scaffold™ for Safety and Neurologic Recovery in Subjects
with Complete Thoracic AIS A Spinal Cord Injury. BWH is a teaching
hospital of Harvard Medical School and hosts one of the largest
neurosurgical intensive care units in the country.
“Patients who suffer spinal cord injury face limited options for
treatment. I’m hopeful that spinal cord research, particularly in
the area of axon regeneration, will expand the options available to
these patients with devastating injuries,” Yi Lu, M.D., Ph.D., said
this week. Dr. Lu is a neurosurgeon at Brigham and Women’s
Hospital, assistant professor of neurosurgery at Harvard Medical
School, and Principal Investigator at the study site.
Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to
welcome Dr. Lu and the team at BWH to the INSPIRE Study. Dr. Lu is
an active clinician scientist in the field of spinal cord injury,
having won the 2011 Spinal Cord Injury Award given by the AANS/CNS
Section on Neurotrauma and Critical Care.”
There are now 31 clinical sites participating in the clinical
study:
- Allegheny General Hospital, Pittsburgh,
PA
- Banner University Medical Center,
Tucson, AZ
- Barnes-Jewish Hospital at Washington
University Medical Center, St. Louis, MO
- Barrow Neurological Institute – St.
Joseph’s Hospital and Medical Center, Phoenix, AZ
- Ben Taub Hospital/Baylor College of
Medicine, Houston, TX
- Beth Israel Deaconess Medical Center,
Boston, MA
- Brigham and Women’s Hospital,
Boston, MA
- Carolina Neurosurgery and Spine
Associates/Carolinas Rehabilitation, Charlotte, NC
- Cooper Neurological Institute, Camden,
NJ
- Foothills Medical Centre, Calgary,
Alberta, Canada
- Goodman Campbell Brain and
Spine/Indiana University Health Neuroscience Center, Indianapolis,
IN
- Hospital of the University of
Pennsylvania, Philadelphia, PA
- Keck Hospital of University of Southern
California, Los Angeles, CA
- Medical College of Wisconsin/Froedtert
Hospital, Milwaukee, WI
- Mount Sinai Hospital, New York, NY
- Northwestern Medicine, Chicago, IL
- Oregon Health & Science University,
Portland, OR
- Rhode Island Hospital, Providence,
RI
- Rutgers New Jersey Medical School,
Newark, NJ
- St. Michael’s Hospital, Toronto,
Ontario, Canada
- Thomas Jefferson University Hospital,
Philadelphia, PA
- Toronto Western Hospital, Toronto, ON,
Canada
- University of California, Davis Medical
Center, Sacramento, CA
- University of California, San Diego
Medical Center, San Diego, CA
- University of Iowa Hospitals and
Clinics, Iowa City, IA
- University of Kansas Medical Center,
Kansas City, KS
- University of Louisville Hospital,
Louisville, KY
- University of New Mexico Hospital,
Albuquerque, NM
- University of Pittsburgh Medical Center
Presbyterian, Pittsburgh, PA
- University of Virginia Health System,
Charlottesville, VA
- Vidant Medical Center, Greenville,
NC
For more information, please visit the company’s
ClinicalTrials.gov registration site:
http://clinicaltrials.gov/ct2/show/study/NCT02138110
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional
healing, thereby reducing post-traumatic cavity formation, sparing
white matter, and allowing neural regeneration across the healed
wound epicenter. The Neuro-Spinal Scaffold, an investigational
device, has received a Humanitarian Use Device (HUD) designation
and currently is being evaluated in the INSPIRE pivotal probable
benefit study for the treatment of patients with acute, complete
(AIS A), thoracic traumatic spinal cord injury and a pilot study
for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord
injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
Safe Harbor StatementAny statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements within the meaning of the federal
securities laws. These statements can be identified by words such
as "believe," "anticipate," "intend," "estimate," "will," "may,"
"should," "expect," “designed to,” “potentially,” and similar
expressions, and include statements regarding the safety and
effectiveness of the Neuro-Spinal Scaffold and pace of enrollment.
Any forward-looking statements contained herein are based on
current expectations, and are subject to a number of risks and
uncertainties. Factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the company’s
ability to successfully open additional clinical sites for
enrollment and to enroll additional patients; the timing of the
Institutional Review Board process; the company’s ability to
commercialize its products; the company’s ability to develop,
market and sell products based on its technology; the expected
benefits and efficacy of the company’s products and technology in
connection with the treatment of spinal cord injuries; the
availability of substantial additional funding for the company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and other
risks associated with the company’s business, research, product
development, regulatory approval, marketing and distribution plans
and strategies identified and described in more detail in the
company’s Annual Report on Form 10-K for the year ended December
31, 2016, and its other filings with the SEC, including the
company’s Form 10-Qs and current reports on Form 8-K. The company
does not undertake to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170410005163/en/
InVivo TherapeuticsHeather Hamel, 617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024